#230 Cancer Pharmacogenetics with Dr. Jamie Fettig
As you may have heard, we are launching a Patreon! For those that don’t know what Patreon is, it’s a platform that allows creators (like podcasters) to offer their followers more content, experiences, and even gifts. We have a survey that will be open for a limited time so get your input in now so we can provide the benefits you want. Maybe that’s a one-on-one Zoom with me for mentorship or a genetics book/movie club or an appearance on the podcast! Let us know so we can make sure to offer it. Thanks for all your support for the podcast over the years.
My guest today is Dr. Jamie Fettig, the Founder and CEO of TruGene Diagnostics. We are chatting about a breakthrough in eliminating variants of unknown significance - especially in relation to companion diagnostic tests and pharmacogenetics in oncology.
Dr. Jamie Fettig is the Founder and CEO of TruGene Diagnostics, which is eliminating variants of unknown significance - especially in relation to companion diagnostic tests and pharmacogenetics in oncology. He graduated from Palmer University. Dr. Fettig previously worked in private practice and then transitioned into manufacturing and selling medical equipment. He also worked as a coach and trainer to fellow doctors.
On This Episode We Discuss:
Defining variants of unknown significance (VUS), pharmacogenetics and companion diagnostics
What TruGene Diagnostics does
The GiggaAssay
How knowing if a breast cancer is HER2+ can help inform medications that people should be prescribed
VUS in HER2 Tyrosine Kinase Region
What people should do if they get HER2+ cancer or their doctor wants to do a biopsy thinking it might be HER2+
How cancer survival rates are impacted by utilizing precision medicine approaches with drugs
How TruGene Diagnostics’ test differs from other PGx tests or Precision Meds
How pharmacogenomics can increase the efficacy of clinical trials
Check out Dr. Fettig’s papers:
Heligenics: fulfilling the promise of the functional genome to enable precision medicine (March, 2023)
Data Supporting a saturation mutagenesis assay for Tat-driven transcription with the GigaAssay (September 2022)
GigaAssay – a high-throughput assay system for molecular functions and cell processes (July 2021)
Check out DNA Today Episode 134 that Kira mentioned during this episode; it’s with guest Dr. Kat Arney about cancer evolution. You can also stream other episodes about pharmacogenomics including
